<< Prone ventilation for ARDS patients does not lower mortality rate, says new study | AMA's Prescribing Data Restriction Program >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Norsk | Русский | Svenska | Polski

Pfizer to close 6 R&D sites, lay off 2,000

Published on November 11, 2009 at 5:49 AM · No Comments

Early Monday morning, the buzz at the International Society of Pharmaceutical Engineers (ISPE) conference in San Diego, California, was that Pfizer Incorporated (NYSE:PFE) (New York, New York) was planning to sell its massive St. Louis/Chesterfield, Missouri, research site to Monsanto Company (NYSE:MON) (St. Louis).

By day's end, the truth had proven to be more dramatic than the rumors: To achieve a 35% reduction in global square footage, the company is going to close six research and development sites across the United States and lay off an estimated 2,000 people.

SOURCE: Industrial Info Resources

Posted in:

Tags:

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading